BIOGEN INC (IDP.DE) Stock Fundamental Analysis
FRA:IDP - Deutsche Boerse Ag - US09062X1037 - Common Stock - Currency: EUR
Taking everything into account, IDP scores 5 out of 10 in our fundamental rating. IDP was compared to 73 industry peers in the Biotechnology industry. While IDP belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. IDP is valued quite cheap, but it does not seem to be growing. This makes IDP very considerable for value investing!
1. Profitability
1.1 Basic Checks
IDP had positive earnings in the past year.
IDP had a positive operating cash flow in the past year.
IDP had positive earnings in each of the past 5 years.
IDP had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of IDP (5.28%) is better than 82.19% of its industry peers.
IDP has a Return On Equity of 8.71%. This is amongst the best in the industry. IDP outperforms 82.19% of its industry peers.
IDP's Return On Invested Capital of 9.95% is amongst the best of the industry. IDP outperforms 87.67% of its industry peers.
The Average Return On Invested Capital over the past 3 years for IDP is below the industry average of 13.21%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.28% | ||
| ROE | 8.71% | ||
| ROIC | 9.95% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
1.3 Margins
IDP's Profit Margin of 15.07% is amongst the best of the industry. IDP outperforms 82.19% of its industry peers.
In the last couple of years the Profit Margin of IDP has declined.
With an excellent Operating Margin value of 26.30%, IDP belongs to the best of the industry, outperforming 89.04% of the companies in the same industry.
IDP's Operating Margin has declined in the last couple of years.
The Gross Margin of IDP (75.58%) is better than 73.97% of its industry peers.
IDP's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.3% | ||
| PM (TTM) | 15.07% | ||
| GM | 75.58% |
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), IDP is creating some value.
Compared to 1 year ago, IDP has more shares outstanding
Compared to 5 years ago, IDP has less shares outstanding
Compared to 1 year ago, IDP has an improved debt to assets ratio.
2.2 Solvency
IDP has an Altman-Z score of 2.75. This is not the best score and indicates that IDP is in the grey zone with still only limited risk for bankruptcy at the moment.
IDP's Altman-Z score of 2.75 is fine compared to the rest of the industry. IDP outperforms 75.34% of its industry peers.
The Debt to FCF ratio of IDP is 2.74, which is a good value as it means it would take IDP, 2.74 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 2.74, IDP belongs to the best of the industry, outperforming 89.04% of the companies in the same industry.
A Debt/Equity ratio of 0.27 indicates that IDP is not too dependend on debt financing.
The Debt to Equity ratio of IDP (0.27) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 2.74 | ||
| Altman-Z | 2.75 |
ROIC/WACC1.1
WACC9.06%
2.3 Liquidity
A Current Ratio of 1.44 indicates that IDP should not have too much problems paying its short term obligations.
IDP has a Current ratio of 1.44. This is in the lower half of the industry: IDP underperforms 63.01% of its industry peers.
IDP has a Quick Ratio of 1.01. This is a normal value and indicates that IDP is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.01, IDP is not doing good in the industry: 68.49% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.44 | ||
| Quick Ratio | 1.01 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 3.06% over the past year.
The earnings per share for IDP have been decreasing by -13.31% on average. This is quite bad
Looking at the last year, IDP shows a small growth in Revenue. The Revenue has grown by 1.59% in the last year.
The Revenue has been decreasing by -7.62% on average over the past years.
EPS 1Y (TTM)3.06%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%-17.71%
Revenue 1Y (TTM)1.59%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%6.13%
3.2 Future
Based on estimates for the next years, IDP will show a small growth in Earnings Per Share. The EPS will grow by 1.94% on average per year.
The Revenue is expected to decrease by -0.29% on average over the next years.
EPS Next Y-7.16%
EPS Next 2Y-2.11%
EPS Next 3Y0.35%
EPS Next 5Y1.94%
Revenue Next Year-3.85%
Revenue Next 2Y-2.85%
Revenue Next 3Y-1.54%
Revenue Next 5Y-0.29%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
IDP is valuated reasonably with a Price/Earnings ratio of 8.14.
Based on the Price/Earnings ratio, IDP is valued cheaper than 94.52% of the companies in the same industry.
IDP is valuated cheaply when we compare the Price/Earnings ratio to 26.35, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 8.16, the valuation of IDP can be described as very reasonable.
97.26% of the companies in the same industry are more expensive than IDP, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.20, IDP is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.14 | ||
| Fwd PE | 8.16 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of IDP indicates a rather cheap valuation: IDP is cheaper than 91.78% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, IDP is valued cheaper than 95.89% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.22 | ||
| EV/EBITDA | 6.86 |
4.3 Compensation for Growth
The decent profitability rating of IDP may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.11%
EPS Next 3Y0.35%
5. Dividend
5.1 Amount
No dividends for IDP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:IDP (5/27/2025, 7:00:00 PM)
113.35
+3.3 (+3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners94.24%
Inst Owner ChangeN/A
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap16.61B
Analysts72.56
Price Target155.05 (36.79%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.97%
Min EPS beat(2)0.67%
Max EPS beat(2)17.28%
EPS beat(4)4
Avg EPS beat(4)13.01%
Min EPS beat(4)0.67%
Max EPS beat(4)28.61%
EPS beat(8)8
Avg EPS beat(8)8.78%
EPS beat(12)12
Avg EPS beat(12)10.47%
EPS beat(16)14
Avg EPS beat(16)9.94%
Revenue beat(2)2
Avg Revenue beat(2)3.39%
Min Revenue beat(2)0.11%
Max Revenue beat(2)6.67%
Revenue beat(4)3
Avg Revenue beat(4)1.89%
Min Revenue beat(4)-0.68%
Max Revenue beat(4)6.67%
Revenue beat(8)5
Avg Revenue beat(8)0.61%
Revenue beat(12)8
Avg Revenue beat(12)1.03%
Revenue beat(16)11
Avg Revenue beat(16)1.28%
PT rev (1m)-16.52%
PT rev (3m)-30.15%
EPS NQ rev (1m)-0.52%
EPS NQ rev (3m)-0.47%
EPS NY rev (1m)-4.93%
EPS NY rev (3m)-5.41%
Revenue NQ rev (1m)-0.21%
Revenue NQ rev (3m)-0.46%
Revenue NY rev (1m)0.48%
Revenue NY rev (3m)0.65%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.14 | ||
| Fwd PE | 8.16 | ||
| P/S | 1.92 | ||
| P/FCF | 8.22 | ||
| P/OCF | 7.31 | ||
| P/B | 1.11 | ||
| P/tB | 20.57 | ||
| EV/EBITDA | 6.86 |
EPS(TTM)13.93
EY12.29%
EPS(NY)13.9
Fwd EY12.26%
FCF(TTM)13.8
FCFY12.17%
OCF(TTM)15.51
OCFY13.69%
SpS58.99
BVpS102.04
TBVpS5.51
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.28% | ||
| ROE | 8.71% | ||
| ROCE | 11.36% | ||
| ROIC | 9.95% | ||
| ROICexc | 11.23% | ||
| ROICexgc | 55.5% | ||
| OM | 26.3% | ||
| PM (TTM) | 15.07% | ||
| GM | 75.58% | ||
| FCFM | 23.39% |
ROA(3y)7.52%
ROA(5y)9.06%
ROE(3y)13.45%
ROE(5y)18.41%
ROIC(3y)10.57%
ROIC(5y)13.65%
ROICexc(3y)12.43%
ROICexc(5y)16.11%
ROICexgc(3y)38.35%
ROICexgc(5y)40.12%
ROCE(3y)12.07%
ROCE(5y)15.58%
ROICexcg growth 3Y14.15%
ROICexcg growth 5Y-5.35%
ROICexc growth 3Y-15.93%
ROICexc growth 5Y-20.8%
OM growth 3Y-4.87%
OM growth 5Y-12.22%
PM growth 3Y5.99%
PM growth 5Y-16.26%
GM growth 3Y-1.51%
GM growth 5Y-2.23%
F-Score6
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 2.74 | ||
| Debt/EBITDA | 1.38 | ||
| Cap/Depr | 40.34% | ||
| Cap/Sales | 2.91% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 78.44% | ||
| Profit Quality | 155.18% | ||
| Current Ratio | 1.44 | ||
| Quick Ratio | 1.01 | ||
| Altman-Z | 2.75 |
F-Score6
WACC9.06%
ROIC/WACC1.1
Cap/Depr(3y)54.43%
Cap/Depr(5y)68.89%
Cap/Sales(3y)3.09%
Cap/Sales(5y)3.21%
Profit Quality(3y)99.34%
Profit Quality(5y)120.98%
High Growth Momentum
Growth
EPS 1Y (TTM)3.06%
EPS 3Y-4.95%
EPS 5Y-13.31%
EPS Q2Q%-17.71%
EPS Next Y-7.16%
EPS Next 2Y-2.11%
EPS Next 3Y0.35%
EPS Next 5Y1.94%
Revenue 1Y (TTM)1.59%
Revenue growth 3Y-4.13%
Revenue growth 5Y-7.62%
Sales Q2Q%6.13%
Revenue Next Year-3.85%
Revenue Next 2Y-2.85%
Revenue Next 3Y-1.54%
Revenue Next 5Y-0.29%
EBIT growth 1Y21.69%
EBIT growth 3Y-8.8%
EBIT growth 5Y-18.9%
EBIT Next Year9.62%
EBIT Next 3Y4.45%
EBIT Next 5Y5.69%
FCF growth 1Y61.56%
FCF growth 3Y-9.06%
FCF growth 5Y-17.06%
OCF growth 1Y53.87%
OCF growth 3Y-7.56%
OCF growth 5Y-16.49%